ORMP
Oramed Pharmaceuticals Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
1.84
PEG
0.00
P/B
0.71
P/S
69.16
EV/EBITDA
-6.18
DCF Value
$1.07
FCF Yield
-9.5%
Div Yield
7.3%
Margins & Returns
Gross Margin
0.7%
Operating Margin
-754.4%
Net Margin
3766.2%
ROE
43.1%
ROA
77.2%
ROIC
-19.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $21.3M | $0.25 |
| FY 2025 | $2.0M | $75.3M | $1.50 |
| Q3 2025 | $0.00 | $48.4M | $1.13 |
| Q2 2025 | $0.00 | $13.3M | $0.31 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.25
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.